Sugi Predict

Sugi Predict / Targets / ADM2

ADM2

Protein ADM2 · Q7Z4H4 · ADM2 on Sugi Atlas →

2,338 patent compounds predicted against ADM2, 1,623 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL13053541 SCHEMBL13053541 0.72 20/20
SCHEMBL13053542 SCHEMBL13053542 0.72 20/20
SCHEMBL13053534 SCHEMBL13053534 0.69 20/20
SCHEMBL14190153 SCHEMBL14190153 0.61 20/20
SCHEMBL13053532 SCHEMBL13053532 0.59 20/20
SCHEMBL13053535 SCHEMBL13053535 0.59 20/20
SCHEMBL550131 SCHEMBL550131 0.60 19/20
SCHEMBL10282928 SCHEMBL10282928 0.59 19/20
SCHEMBL3034499 SCHEMBL3034499 0.58 19/20
SCHEMBL10282927 SCHEMBL10282927 0.57 19/20
SCHEMBL13053543 SCHEMBL13053543 0.65 18/20
SCHEMBL14042043 SCHEMBL14042043 0.65 18/20
SCHEMBL13053545 SCHEMBL13053545 0.64 17/20
SCHEMBL14069104 SCHEMBL14069104 0.62 17/20
SCHEMBL14069223 SCHEMBL14069223 0.55 17/20
SCHEMBL14069415 SCHEMBL14069415 0.55 17/20
SCHEMBL10193456 SCHEMBL10193456 0.51 17/20
SCHEMBL13053551 SCHEMBL13053551 0.59 16/20
SCHEMBL13053550 SCHEMBL13053550 0.59 16/20
SCHEMBL13053561 SCHEMBL13053561 0.50 16/20

Clinical trials — most relevant to ADM2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients PHASE4RECRUITING
L-arginine Treatment in Mild Hypertension PHASE4UNKNOWN
Vascular Function Intervention Trial in Sickle Cell Disease PHASE2/PHASE3UNKNOWN
Effect of Rosiglitazone on ADMA in Critical Illness PHASE3UNKNOWN
L-Arginine in Pre-Eclampsia PHASE3COMPLETED
STRETCH Study: Effect of Distensibility on Endothelial-Dependent Vasoreactivity in Patients With ISH PHASE2COMPLETED
The STRETCH Study: Distensibility on Endothelial-Dependent Vasoreactivity in Subjects With Systolic Hypertension PHASE2COMPLETED
Oral L-Citrulline and ADMA in Pregnancy PHASE1COMPLETED
Effects of Growth Hormone on the Nitric Oxide Pathway PHASE1COMPLETED
Assessment of Disease Severity, Progression and Treatment in Infected Patients Presenting to the Emergency Department nanCOMPLETED
Proadrenomedullin for Early Risk Assessment in the Emergency Department nanCOMPLETED
L-arginine and Asymmetric Dimethylarginine (ADMA) and Lifestyle Protocols nanCOMPLETED
Haemodialysis Salt Reduction Study nanCOMPLETED
L-Arginine, Symmetrical and Asymmetrical Dimethylarginine (SDMA/ADMA) in Acute Kidney Injury (AKI) nanCOMPLETED
Adrenomedullin and Outcome in Severe Sepsis and Septic Shock nanCOMPLETED
Angiotensin Converting Enzyme (ACE) Inhibition and Cardiac Allograft Vasculopathy nanCOMPLETED
Sodium-Endothelial Function-CKD Study nanCOMPLETED
Prognostic Value of Protein IMP3 Expression in Cervical Cancer nanCOMPLETED
Correlation Between Serum Markers of Unstable Plaque and Virtual Histology of Unstable Plaque Visualized by IVUS nanCOMPLETED
The Role of L-arginine in the Endothelial Dysfunction nanWITHDRAWN
MR-proADM as a Early Biomarker for DGF and AR in Kidney and Liver Transplantation nanRECRUITING
Pituitary Derived-Intermedin is an Estrogen-Modulated Factor for Reducing Blood Pressure nanUNKNOWN
Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms nanCOMPLETED
Evaluation of Oxidative Stress and Methylated Arginine Levels in Individuals With Periodontitis nanCOMPLETED
Relationship of Haptoglobin Phenotype to Vascular Function and Response to Vitamin E Supplementation in Patients With Diabetes Mellitus Type 2: The EVAS Trial nanUNKNOWN
Glucagon Like Peptide-1 in Remote Ischemic Conditioning nanCOMPLETED
Study of Pregnancy Regulation of Insulin and Glucose nanCOMPLETED
Nebivolol Versus Sustained Release Metoprolol Succinate in Patients With Chronic Kidney Disease nanCOMPLETED
The Effect of Exercise Training on Skeletal Muscle Metabolism in Peripheral Artery Disease (PAD) nanUNKNOWN
Autophagy/Apoptosis Balance in Placental Vascular Pathologies nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a ADM2 binder may also engage these)

ProteinNameSimilarity
P61312 — 1.000 P61312 →
Q7TNK8 — 0.992 Q7TNK8 →
P01142 — 0.984 P01142 →
P84715 — 0.983 P84715 →
B0VXV8 — 0.983 B0VXV8 →
Q2PE51 — 0.982 Q2PE51 →
D5J9S0 — 0.980 D5J9S0 →
P55089 — 0.980 P55089 →
P01143 — 0.979 P01143 →
P83859 — 0.979 P83859 →
P51461 — 0.979 P51461 →
P16860 — 0.979 P16860 →
Q9Z0L2 — 0.979 Q9Z0L2 →
P11384 — 0.979 P11384 →
D4A9R4 — 0.978 D4A9R4 →
Q95MI6 — 0.978 Q95MI6 →
P0C7P5 — 0.978 P0C7P5 →
P27106 — 0.978 P27106 →
P56469 — 0.977 P56469 →
P07492 — 0.976 P07492 →
Q8CE23 — 0.976 Q8CE23 →
P13204 — 0.976 P13204 →
P13083 — 0.976 P13083 →
Q863C3 — 0.975 Q863C3 →
Q6P1B3 — 0.975 Q6P1B3 →
Q62949 — 0.975 Q62949 →
Q08535 — 0.975 Q08535 →
Q7TSB7 — 0.975 Q7TSB7 →
P09683 — 0.975 P09683 →
P83862 — 0.975 P83862 →